美股異動丨京東(JD.US)盤前漲近5% 成功發行2022年首單規模10億元疫情防控ABS
格隆匯4月22日丨京東(JD.US)盤前漲近5%,報53.18美元。京東科技集團下屬企業上海邦匯商業保理有限公司作為原始權益人,華泰證券(上海)資產管理有限公司擔任計劃管理人,國泰君安證券擔任聯合銷售機構,京東科技-京誠系列6號3期供應鏈保理合同債權資產支持專項計劃(疫情防控ABS)在上海證券交易所支持下成功發行,發行規模為10億元。該項目是2022年以來全市場首單疫情防控主題資產證券化項目,也是京東首單疫情防控ABS項目。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.